Australia's most trusted
source of pharma news
Thursday, 21 November 2024
Posted 20 November 2024 AM
It's the highest selling drug in the world but MSD's Keytruda had better watch out with moves underway by rivals to steal the immunotherapy's crown.
BioNTech is the latest company to claim it has found "the next-generation immune modulator", announcing late last week it would fork out US$800 million upfront to buyout China-based Biotheus, plus up to US$150 million in milestone payments.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.